TY - JOUR
T1 - Transfusion use and effect on progression-free, overall survival, and quality of life in upfront treatment of advanced epithelial ovarian cancer
T2 - Evaluation of the European Organization for Research and Treatment EORTC-55971 Cohort
AU - Prescott, Lauren Shore
AU - Vergote, Ignace
AU - Sun, Charlotte C.
AU - Bodurka, Diane C.
AU - Coleman, Robert
N1 - Funding Information:
This research was supported in part by the National Institutes of Health through MD Anderson Cancer Center’s support grant CA016672, the Ann Rife Cox Chair in Gynecology, and the Judy Reis/Al Pisani, MD Ovarian Cancer Research Fund. LSP was supported for work on this projectb y a NIH T32 grant, Training of Academic Gynecologic Oncologists, from the National Cancer Institute (5T32-CA101642).
Publisher Copyright:
© 2022 BMJ Publishing Group. All rights reserved.
PY - 2022/11/10
Y1 - 2022/11/10
N2 - Background The impact of blood transfusion on ovarian cancer survival is uncertain. Objective To investigate whether peri-operative blood transfusion negatively impacted progression-free survival, overall survival, and quality of life in patients with advanced ovarian cancer. Methods We performed an ancillary analysis of the European Organization for Research and Treatment (EORTC) 55971 phase III trial, in which patients were randomized to primary debulking surgery versus neoadjuvant chemotherapy. Patients included in the per-protocol analysis were categorized by receipt of a transfusion. Results 612 of 632 (97%) of patients had adequate data for analysis. Of those, 323 (53%) received a transfusion. The transfusion cohort was more likely to have had better Word Health Organization (WHO) performance status, serous histology, undergone primary debulking surgery, and received more aggressive surgery, with higher rates of no gross residual disease. Median overall survival was 34.0 vs 35.2 months in the no transfusion and transfusion cohorts (p=0.97). The adjusted HR for death was 1.18 (95% CI 0.94 to 1.48) in favor of the transfusion cohort. Median progression-free survival was 13.6 vs 12.6 months in the no transfusion and transfusion cohorts (p=0.96). The adjusted HR for progression was 1.14 (95% CI 0.91 to 1.43). There were no significant differences in global quality of life, fatigue, dyspnea, or physical functioning between the two cohorts at baseline or at any of the four assessment times. Grade 3 and 4 surgical site infections were more common in the transfusion cohort. Conclusion Transfusion did not negatively impact progression-free survival or overall survival; however, it was associated with increased peri-operative morbidity without improvements in quality of life.
AB - Background The impact of blood transfusion on ovarian cancer survival is uncertain. Objective To investigate whether peri-operative blood transfusion negatively impacted progression-free survival, overall survival, and quality of life in patients with advanced ovarian cancer. Methods We performed an ancillary analysis of the European Organization for Research and Treatment (EORTC) 55971 phase III trial, in which patients were randomized to primary debulking surgery versus neoadjuvant chemotherapy. Patients included in the per-protocol analysis were categorized by receipt of a transfusion. Results 612 of 632 (97%) of patients had adequate data for analysis. Of those, 323 (53%) received a transfusion. The transfusion cohort was more likely to have had better Word Health Organization (WHO) performance status, serous histology, undergone primary debulking surgery, and received more aggressive surgery, with higher rates of no gross residual disease. Median overall survival was 34.0 vs 35.2 months in the no transfusion and transfusion cohorts (p=0.97). The adjusted HR for death was 1.18 (95% CI 0.94 to 1.48) in favor of the transfusion cohort. Median progression-free survival was 13.6 vs 12.6 months in the no transfusion and transfusion cohorts (p=0.96). The adjusted HR for progression was 1.14 (95% CI 0.91 to 1.43). There were no significant differences in global quality of life, fatigue, dyspnea, or physical functioning between the two cohorts at baseline or at any of the four assessment times. Grade 3 and 4 surgical site infections were more common in the transfusion cohort. Conclusion Transfusion did not negatively impact progression-free survival or overall survival; however, it was associated with increased peri-operative morbidity without improvements in quality of life.
KW - Ovarian Neoplasms
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=85143546892&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143546892&partnerID=8YFLogxK
U2 - 10.1136/ijgc-2022-003947
DO - 10.1136/ijgc-2022-003947
M3 - Article
C2 - 36356982
AN - SCOPUS:85143546892
SN - 1048-891X
VL - 33
SP - 1
EP - 9
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
IS - 1
ER -